Valeant has drawn scrutiny from Congress, hospitals and patients for sharply increasing their prices, the NYT reports.» Read More
CNBC's Meg Tirrell covers the allegations surrounding Valeant Pharmaceuticals, and highlights concerns with Turing prices.
Theranos, the blood-testing start-up that recently came under fire, continued to defend its technology with a blog post on Thursday.
Former Medtronic CEO Bill George, discusses the controversy surrounding allegation of improper accounting at Valeant Pharmaceuticals. But Ken Langone, Invemed Associates, counters he would bet his last dollar there are no accounting issues there at all.
John Lechleiter, Eli Lilly chairman & CEO, discusses the impact of the strong dollar on revenues as the company posts mixed quarterly results which beat on earnings. Also Lechleiter provides an outlook on several drugs, including data on clinical trials for its diabetes drug.
CNBC's Meg Tirrell has the update on Valeant following a chaotic day for the stock after allegations of improper accounting from Citron Research surfaced.
Peder Holk Nielsen, CEO of Novozymes, says manufacturers of biofuels are under pressure due to low oil prices, which is holding back growth.
John Petrides, MD and portfolio manager at Point View Wealth Management, says it might not be a wise decision to follow Bill Ackman into Valeant stock.
Hedge fund manager Bill Ackman buys 2 million additional shares in Valeant, reports CNBC's Scott Wapner.
CNBC's Meg Tirrell reports an explosive short-seller report from Citron Research that has caused a halt in trading for shares of Valeant.
Theranos CEO Elizabeth Holmes fought back on Wednesday against accusations over her company's tech.
Biogen says it's cutting about 11 percent of its workforce and ending some development programs in a restructuring aimed to save $250 million a year.
CNBC's Meg Tirrell reports Biogen tops Street estimates and announces a restructuring plan that includes cutting the workforce and ending some pipeline programs.
Jean Paul Clozel, CEO of Actelion, talks about plans for acquiring ZS Pharma and whether or not his company could be targeted for a merger with a larger company.
Jean Paul Clozel, CEO of Actelion, expects sales of Tracleer, a medicine for high blood pressure, to decline slowly when it becomes generic.
Despite recent drug price controversies, Valeant has had strong growth in areas such as unit volume, says David Steinberg, MD of equity research at Jefferies.
The CDC recommends everyone in the U.S. older than six months receive a flu shot. Here's what you need to know.
The market for influenza vaccines globally is estimated to be about $4 billion, and growing.
The flu vaccine is big business. CNBC examines what goes into a flu shot and why they’re still grown in chicken eggs.
John Carreyrou, The Wall Street Journal reporter behind a disputed piece on biotech start-up Theranos, defends his story.
For Valeant investors, the bad news is that the bad news seemingly keeps on coming.
Get the best of CNBC in your inbox